Current treatment options to prevent perinatal transmission of herpes simplex virus

@article{Leung2003CurrentTO,
  title={Current treatment options to prevent perinatal transmission of herpes simplex virus},
  author={Daniel T. Leung and Stephen L. Sacks},
  journal={Expert Opinion on Pharmacotherapy},
  year={2003},
  volume={4},
  pages={1809 - 1819}
}
Neonatal herpes is a potentially devastating consequence of perinatal transmission of the herpes simplex virus (HSV), with significant morbidity and mortality. Treatment options are available, but must begin early in disease with manifestations that are often protean. Thus, preventive measures need to be optimised. Antiviral suppression in late pregnancy of women with a history of recurrent genital herpes will decrease symptomatic recurrence at delivery and appears to reduce caesarian section… Expand
Herpes simplex virus infections of the newborn
TLDR
Despite therapy with acyclovir, the best available anti-HSV drug, a substantial number of HSV-infected infants with disseminated infections or encephalitis die or have long-term neurodevelopmental sequelae. Expand
Herpes Simplex Virus Infections of the Newborn.
TLDR
Despite therapy with acyclovir, the best available anti-HSV drug, a substantial number of HSV-infected infants with disseminated infections or encephalitis die or have long-term neurodevelopmental sequelae. Expand
Herpes simplex virus in pregnancy: new concepts in prevention and management.
TLDR
Genital herpes simplex virus (HSV) infection is one of the most common viral sexually transmitted diseases in the United States, but it is frequently under-recognized and only a small percentage of women are aware of being infected with HSV. Expand
Recent Advances In Intrauterine Infections
Intrauterine infections (IUI) can be transmitted transplacentally or occur due to events related to birth and early neonatal contact with pathogens. TORCH, as an acronym, stands for Toxoplasmosis,Expand
Inadequacy of plasma acyclovir levels at delivery in patients with genital herpes receiving oral acyclovir suppressive therapy in late pregnancy.
  • D. Leung, P. Henning, +5 authors D. Money
  • Medicine
  • Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC
  • 2009
TLDR
Oral dosing of acyclovir in women in late pregnancy may result in insufficient levels at delivery to prevent viral shedding, and alternative approaches that incorporate acyClovir dosing through labour, either through oral or intravenous administration, should be evaluated to assess effects on viral shedding. Expand
GEITAL HERPES DISEASES: A OVERVIEW
TLDR
The standard, effective and specific treatment for genital herpes is antiviral therapy with drugs like Valacyclovir and Acyclovir combined with analgesics like Aspirin or Paracetamol. Expand
Mucosal Herpes Immunity and Immunopathology to Ocular and Genital Herpes Simplex Virus Infections
TLDR
The phenotypic and functional properties of innate and adaptive mucosal immune cells, their role in antiherpes immunity, and immunopathology are reviewed and the progress and limitations in developing a safe and efficient mucosal herpes vaccine are discussed. Expand
Identity of zinc finger nucleases with specificity to herpes simplex virus type II genomic DNA: novel HSV-2 vaccine/therapy precursors
  • M. Wayengera
  • Biology, Medicine
  • Theoretical Biology and Medical Modelling
  • 2011
TLDR
The therapeutic-potential of zinc finger arrays (ZFAs) and ZFNs is identified and modeled, with unique specificity to the HSV-2 genome. Expand
Shallominthe Active Antimicrobial Constituent of Persian Shallot in Treatment of Oral Herpes: A Double-Blind Randomized Clinical Trial
TLDR
The results of this study demonstrated that shallomin is a useful natural remedy in preventing the progression and treatment of cold sores and can significantly reduce the duration of ulceration. Expand
Computational Approach for Structure Based Drug Design from a Series ofNatural Antiviral Compounds for Herpesviridae Family
TLDR
This paper is the focus on the development of structure-based drug design for HHV infection that involves choosing the target proteins, visualizing the target structure, identifying the binding site, docking the ligands, and evaluating those using computational techniques. Expand
...
1
2
...

References

SHOWING 1-10 OF 111 REFERENCES
Natural history of neonatal herpes simplex virus infections in the acyclovir era.
TLDR
Comparisons between patients treated in the periods between 1981-1988 and 1989-1997 according to extent of disease revealed that the mean time between the onset of disease symptoms and initiation of therapy has not changed significantly from the early 1980s to the late 1990s, demonstrating that no progress has been made in decreasing the interval between onset of HSV symptoms and initiated antiviral therapy. Expand
Effects on infants of a first episode of genital herpes during pregnancy.
TLDR
It is concluded that infants born to women who acquire primary genital herpes during pregnancy are at high risk of exposure to HSV, either during premature labor at the time of the primary episode or subsequently because of asymptomatic cervical shedding of the virus. Expand
Acyclovir prophylaxis in late pregnancy prevents recurrent genital herpes and viral shedding.
  • S. Braig, D. Luton, +4 authors J. Oury
  • Medicine
  • European journal of obstetrics, gynecology, and reproductive biology
  • 2001
TLDR
The findings underline the value of antiviral prophylaxis in late pregnancy for women with a known history of genital herpes, because it is not applicable to patients with no known clinical history but may excrete the virus. Expand
The natural history of herpes simplex virus infection of mother and newborn.
TLDR
Neither the presence or absence of antibodies to HSV was useful in predicting either presentation or outcome of infection, which further emphasize the complex nature of HSV infections of the newborn and need for tertiary care. Expand
Cost-effectiveness of acyclovir suppression to prevent recurrent genital herpes in term pregnancy.
TLDR
Assuming that prenatal acyclovir treatment is safe for the fetus, utilizing this management for all patients with recurrent HSV in pregnancy could immediately save $183 per patient, which translates to $36,600,000 per year just in reduced obstetrical costs. Expand
Herpes simplex virus infection of the fetus and newborn.
Although infrequent, untreated neonatal herpes results in death in half the cases and neurologic sequelae in three quarters of the survivors. Neonatal infection is usually acquired from maternalExpand
Fatal disseminated herpes simplex in pregnancy with maternal and neonatal death.
TLDR
A case of maternal disseminated HSV with subsequent maternal death at an estimated 31 weeks' gestation in which the diagnosis was made at the time of necropsy and the infant was started on acyclovir therapy but died of disseminatedHSV. Expand
Fatal disseminated herpes simplex in pregnancy with maternal and neonatal death.
TLDR
A case of maternal disseminated HSV with subsequent maternal death at an estimated 31 weeks' gestation in which the diagnosis was made at the time of necropsy and the infant was started on acyclovir therapy but died of disseminatedHSV. Expand
Acyclovir Suppression to Prevent Cesarean Delivery After First‐Episode Genital Herpes
TLDR
Suppressive acyclovir therapy reduced the need for cesarean for recurrent herpes in women whose first clinical episode of genital HSV occurred during pregnancy and did not increase asymptomatic viral shedding and was not harmful to the term fetus. Expand
Pharmacokinetics of acyclovir in the term human pregnancy and neonate.
TLDR
The administration of acyclovir, 400 mg every 8 hours, appears appropriate for use in an efficacy and safety study regarding suppression of herpes simplex virus recurrences during the last weeks of pregnancy. Expand
...
1
2
3
4
5
...